New Tumor Organoid Biobank Exposes MCL-1 as a Drug Target in Rare Sarcomas

Small round cell sarcomas (SRCS) are a family of genetically distinct but clinically similar cancers—including Ewing sarcoma (ES), CIC::DUX4 sarcoma (CDS), and BCOR-rearranged sarcoma (BRS)—that predominantly strike children and young adults. Despite their molecular differences, all subtypes are treated with the same Ewing sarcoma chemotherapy regimen, and outcomes for relapsed or refractory disease remain dismal. CDS in particular shows little to no response to standard chemotherapy. A major obstacle to progress has been the scarcity of reliable, long-term preclinical models beyond Ewing sarcoma cell lines and patient-derived xenografts.

To address this gap, researchers developed a living biobank of SRCS patient-derived tumor organoids, called tumoroids, sourced from fresh diagnostic biopsies, surgical resections, and patient-derived xenograft material. The team optimized three Sarcoma Culture Media formulations containing EGF, FGF2, and IGF1 at varying concentrations. Of 37 patient samples attempted, 33 (89%) yielded stable long-term cultures (defined as growth beyond five passages), with 100% success in treatment-naïve biopsies and PDX-derived samples. The resulting biobank spans multiple fusion genotypes: EWSR1::FLI1, EWSR1::ERG, EWSR1::FEV, CIC::DUX4, BCOR::CCNB3, and KMT2D::BCOR.

Comprehensive molecular characterization using histology, whole-genome sequencing (WGS), and RNA sequencing confirmed that tumoroids faithfully preserved the histological features, known marker gene expression patterns, and chromosomal rearrangements of their matched patient tumors. Importantly, analysis of mutation clusters across patient-matched longitudinal samples demonstrated that cellular heterogeneity is maintained within the tumoroid cultures, a critical quality that distinguishes these models from clonally simplified cell lines.

Drug screening was performed across the tumoroid panel using a library of cytotoxic and targeted compounds. Results revealed clear subtype-specific sensitivities. Most strikingly, CIC::DUX4 sarcoma tumoroids demonstrated pronounced sensitivity to MCL-1 inhibitors—compounds that block the anti-apoptotic protein MCL-1, thereby lowering the apoptotic threshold in cancer cells. This finding was specific to the CDS subtype and was not observed across other SRCS tumoroids, suggesting a genuine biological dependency rather than a pan-toxic effect. Other entity-specific sensitivities to various cytotoxic compounds were also identified across the SRCS subtypes.

This biobank represents a significant methodological advance: it is the first sustained, multi-entity SRCS tumoroid resource and offers a tractable platform for basic cancer biology studies, drug discovery, and eventually personalized medicine approaches. The identification of MCL-1 inhibition as a potential therapeutic strategy for CDS is particularly timely, given this subtype's resistance to current therapy. Caveats include the relatively small number of models per subtype, the in vitro nature of the screen, and the need for in vivo validation before clinical translation.